Status:
COMPLETED
A Study of Abatacept in Participants That Only Recently Started to Develop Rheumatoid Arthritis
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
This is a long-term study of Abatacept in participants that only recently started to develop Rheumatoid Arthritis, a chronic inflammatory disorder affecting mainly joints.
Eligibility Criteria
Inclusion
- Participants recently (within the last 24 months before enrollment) diagnosed with established moderate to severe active RA
- Participants naïve of abatacept and who, at their physician's discretion, are initiated with abatacept according the German label/SmPC (Summary of product characteristics)
Exclusion
- Participants who are currently included in any interventional clinical trial in RA
- Other protocol defined inclusion/exclusion criteria could apply
Key Trial Info
Start Date :
April 17 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2022
Estimated Enrollment :
158 Patients enrolled
Trial Details
Trial ID
NCT03457792
Start Date
April 17 2018
End Date
March 30 2022
Last Update
June 14 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Freiburg im Breisgau, Germany, 79095